PANTHERx Rare Pharmacy was selected by Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) as the exclusive U.S. pharmacy distribution partner for the expanded indication of IMCIVREE (setmelanotide) for adults and children 4 years and older with acquired hypothalamic obesity, according to a company statement.

Acquired hypothalamic obesity is a rare disease characterized by accelerated and sustained weight gain caused by injury to the hypothalamus. The condition most frequently follows the growth or treatment of craniopharyngioma, astrocytoma or other hypothalamic-pituitary tumors, though additional causes may include traumatic brain injury, stroke or inflammation.

PANTHERx will use its RxARECARE model to support patients, caregivers and prescribers with therapy-specific clinical expertise through individualized case management, education and financial navigation services.

"This new indication for IMCIVREE marks an important scientific milestone for individuals and families affected by acquired hypothalamic obesity, a highly complex disease with historically limited therapeutic options," said Bansi Nagji, CEO of PANTHERx Rare.

PANTHERx has served as the exclusive pharmacy distribution partner for IMCIVREE since 2020 for chronic weight management in adult and pediatric patients 2 years and older with obesity due to Bardet-Biedl Syndrome and certain genetic deficiencies.

The Pittsburgh-based company describes itself as the largest independent rare pharmacy in the U.S. and holds dual accreditations in rare disease from the Accreditation Commission for Health Care and Utilization Review Accreditation Commission.